IRIDEX Study Shows MicroPulse Laser Offers Safer, More Precise Glaucoma Treatment
Reuters
Dec 08, 2025
IRIDEX Study Shows MicroPulse Laser Offers Safer, More Precise Glaucoma Treatment
IRIDEX Corporation announced the publication of a new clinical study in Translational Vision Science & Technology examining the thermal dynamics of transscleral laser treatments for glaucoma. The study, led by Dr. Tomas M. Grippo, utilized advanced computer modeling to compare the tissue heating effects of continuous wave transscleral cyclophotocoagulation (CW-TSCPC) and MicroPulse® transscleral laser therapy (MicroPulse TLT) using IRIDEX's Cyclo G6® Laser and associated delivery devices. Results showed that CW-TSCPC produced a wider and hotter thermal zone compared to MicroPulse TLT, which generated a smaller, more uniform heat distribution and maintained lower peak temperatures. The findings, which have already been published, suggest both techniques share a thermal continuum and may be optimized for different clinical roles in glaucoma management.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRIDEX Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597358-en) on December 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.